Do I have a non-hodgkin lymphoma PFAS claim?
There is no way to answer that from a web page alone, but these are the facts a Pennsylvania non-hodgkin lymphoma PFAS claim review actually turns on. If most of them describe your situation, it is worth submitting the intake form.
- A confirmed non-hodgkin lymphoma diagnosis, documented by pathology or an oncology record.
- A PFAS exposure source you can point to — a public water system, a private well, AFFF firefighting foam, a military base, an airport, or an industrial workplace.
- Time spent at that location: where you lived, worked, or served, and roughly which years.
- Diagnosis timing that follows the exposure period, which is what links the two in a claim review.
- Any supporting paperwork — water-test results, utility bills, employment records, or military service records tying you to the location.
Representation of accepted cases is typically on a contingency-fee basis — no attorneys’ fees unless a recovery is obtained. Clients may remain responsible for case costs and expenses; the written retainer will set out how costs are handled. No case outcome is guaranteed.
PFAS linkage
- PFAS exposure has been associated with immune-system effects, including reduced vaccine response and immune modulation.
- Some occupational and environmental studies have explored PFAS exposure and lymphoma risk, though evidence differs by compound, subtype, and population.
- Intake review should include the lymphoma subtype, staging, treatment course, and source of PFAS exposure.
Non-Hodgkin lymphoma symptoms
- Painless swollen lymph nodes in the neck, armpit, or groin
- Unexplained fever, night sweats, or weight loss
- Fatigue, itching, or frequent infections
- Chest pain, cough, shortness of breath, or abdominal fullness depending on lymph-node location
- Easy bruising or bleeding in some cases involving bone marrow
Diagnosis and medical records
- Excisional lymph-node biopsy or core biopsy with pathology review
- Flow cytometry, immunohistochemistry, cytogenetics, or molecular tests to identify subtype
- PET/CT, CT, bone marrow biopsy, or blood tests for staging
- Specialist evaluation by hematology/oncology
Treatment options
- Active monitoring for selected indolent lymphomas
- Chemotherapy, immunotherapy, targeted therapy, or antibody-based regimens
- Radiation therapy for localized disease or symptom control
- Stem-cell transplant, CAR T-cell therapy, or clinical trials for selected relapsed or aggressive disease
What patients should gather for intake
- Save pathology reports showing lymphoma subtype, staging scans, treatment regimens, and response assessments.
- Include infection history, immune problems, and all cancer treatment dates.
- Document contaminated water, firefighting foam, military, airport, industrial, or workplace exposure.
Medical and attorney advertising notice. This page is for general information only and is not medical advice. Talk with your treating clinician about diagnosis and treatment. Submitting an intake form does not create an attorney-client relationship, and cases may be referred to national PFAS co-counsel.